About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Promising New Drug for Advanced Kidney Cancer

by Medindia Content Team on September 27, 2007 at 8:01 PM
Font : A-A+

Promising New Drug for Advanced Kidney Cancer

A new drug has been observed to show promise in patients with advanced kidney cancer where tumours generally don't respond. The study, presented today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.

In the study, scientists gave axitinib to 62 patients whose kidney cancer had spread and who had not benefited from a standard treatment, sorafenib, a targeted therapy designed to disrupt cell division signals in cancer cells and block the tumour's ability to form new blood vessels that help it grow. Fourteen of the patients also had been given - to no avail - another similarly targeted drug, sunitinib, after the sorafenib had failed to work. Axitinib works similarly to the other two but is believed to be more potent.

Advertisement

'More than half the patients - 51 percent - experienced tumour shrinkage and in 23 percent of them the shrinkage is considered significant,' said lead investigator Dr Brian I. Rini, an associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the Pfizer scientific advisory board. 'Preliminary analysis shows the progression-free survival was on average more than 7.7 months. We think these results are impressive because these patients were heavily pre-treated and with drugs thought to be similar to axitinib.

'The disease progressed in only 24 percent of patients, which we think is low in this kind of setting,' Rini added. The study found the tumour remained stable in 37 percent of the patients.
Advertisement

'Historically, metastatic kidney cancer has been very tough to treat, with a median survival of 12 months. Through the results of this trial, it appears that axitinib is a very active drug in renal cell cancer that can benefit a large number of patients,' Rini added.

The drug's maker, Pfizer, paid for the study. Axitinib is also being tested in advanced pancreatic, thyroid, lung and breast cancers.

Source: Eurekalert
GAN /J
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Cancer and Homeopathy Clinical Trials - Different Phases of the trial Urinary Stones In Children Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Signature Drug Toxicity Kidney Disease Cancer Facts Cancer 

Recommended Reading
FDA: New Drug for Advance Kidney Cancer
The U.S. Food and Drug Administration (FDA) today approved Torisel (temsirolimus) for the treatment ...
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Hydronephrosis / Antenatal Counseling
Currently most pregnant women undergo one or two ultrasound scans during their pregnancy....
Urinary Stones In Children
There is a wide misconception that only adults develop stones. On the contrary kidney stones are ver...
Vesico-Ureteric Reflux Causing UTI in Children
Bacterial infection of urinary bladder can cause pain and burning sensation while passing urine. Abn...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use